Annual general meeting of Medigene AG on 24 June 2024
Convenience Translation
Gerd Zettlmeissl, PhD
Year of birth | 1955 | ||||||||
Current place of residence | Vienna, Austria | ||||||||
Current position(s) | Self-employed consultant immunoprophylaxis and immunotherapies | ||||||||
Other current supervisory | Company | Location | Job title | Conflict of | |||||
board | or | nonexecutive | interest | ||||||
mandates | MSD | Wellcome | New Delhi, | Chairman of the | No | ||||
Trust | Hilleman | India | Supervisory | ||||||
Laboratories | Board | ||||||||
Themis | Vienna, | Chairman of the | No | ||||||
Bioscience GmbH | Austria | Supervisory | |||||||
Board | |||||||||
Shareholding in Medigene | ☐ None | ||||||||
☒ Yes, 10.000 | |||||||||
Personal | / | occupational | ☒ None | ||||||
relationship with Medigene | ☐ Yes | ||||||||
or its Management | |||||||||
Relevant | knowledge, skills | More than 25 years of experience in leading positions in both | |||||||
and experience related to | research & development and management in the international | ||||||||
the Medigene mandate | pharmaceutical and biotech industry with focus on immunological | ||||||||
products | |||||||||
10 years of experience as supervisory board member - mostly as | |||||||||
chairman - in a number of international pharmaceutical and biotech | |||||||||
companies |
Professional background
Until early 2015 he was Chairman of the Supervisory Board of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline and until 2020 Chairman of Themis Bioscience (Austria), a vaccine/immunotherapy company acquired by Merck Shark Dhome. He is the former CEO of the Austrian-based biotechnology company Intercell (now Valneva). While at Intercell from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine and oversaw efforts to build and advance a broad-based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology.
Education
- Studies in Biology and Chemistry, University of Regensburg, Germany
- Doctorate in Biochemistry, University of Regensburg, Germany
- Postdoc, Institut Pasteur, Paris, France
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
MediGene AG published this content on 17 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 May 2024 10:18:08 UTC.